Positive top-line pivotal Phase III data results for empagliflozin
Top-line results for four completed Phase III clinical trials...
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
List view / Grid view
Top-line results for four completed Phase III clinical trials...
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
Announces it will begin remainder of pre-planned clinical trials for…
7 January 2013 | By Boehringer Ingelheim
Announces it will begin remainder of pre-planned clinical trials for LY2605541...
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
25 August 2011 | By Boehringer Ingelheim
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
Boehringer Ingelheim and Eli Lilly received a positive opinion from…
24 June 2011 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly received a positive opinion from the EMA's medicinal committee...
Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and…
21 June 2011 | By Eli Lilly and Company
Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to BYDUREON™...
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today…
3 May 2011 | By OgilvyHealthPR
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.1 The FDA has approved linagliptin as a monotherapy…